SKYSCRAPER-02: Primary Results of A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide (CE) with or Without Tiragolumab (tira) in Patients (pts) With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Rudin, Charles M.Liu, Stephen V.Lu, ShunSoo, Ross A.Hong, Min HeeLee, Jong-SeokBryl, MaciejDumoulin, Daphne W.Rittmeyer, AchimChiu, Chao-HuaOzyilkan, OzgurNavarro, AlejandroNovello, SilviaOzawa, YuichiMeng, RaymondHoang, TienLee, AnthonyWen, XiaohuiHuang, MeilinReck, Martin2023-09-252023-09-2520220732-183Xhttp://hdl.handle.net/11727/10786enginfo:eu-repo/semantics/closedAccessSKYSCRAPER-02: Primary Results of A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide (CE) with or Without Tiragolumab (tira) in Patients (pts) With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).Conference Object4017000891791500033